Q3 2024 Embla Medical hf Earnings Call Transcript
¶ -
Good morning, and welcome to the Embla Medical conference call where we will review the third quarter results for 2024. I'm [Sveinn] Solvason, CEO of Embla Medical and joining the joining me today here from Copenhagen is our Chief Financial Officer, Arna Sveinsdottir and Embla Medical's Head of Investor Relations, Klaus Sindahl.
Today we'll discuss the financial performance and progress we've made during the third quarter. The presentation should take roughly 15 minutes after which there will be an opportunity to ask questions during a Q&A session.
If you go to the next slide please, we continue to deliver solid growth. Organic sales growth was 7% and local currency growth was 11% including an impact from M&A and currency. We continue to see a strong momentum in the EMEA driven by prosthetics and neuro products as well as patient care. Our pricing and support business, however, delivered a more modest growth for the quarter.
Our EBITDA margin came in strong at 22% supported by
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |